RxDoctor Payments Data

Gilberto Ramirez, MD

Internal Medicine · Bloomfield, CTNPI 1518981448

Payments from drug & device makers

$12,090in general payments, 2019–2025

Across 627 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$829
  • Boehringer Ingelheim$704
  • Astellas Pharma US Inc$673
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$11,79898%
  • Education$2382%
  • Gifts$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,090 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$87,274
Medicare patients
329
Services billed
1,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin302$225,503
OzempicSemaglutide175$209,177
FarxigaDapagliflozin Propanediol206$154,432
EliquisApixaban336$146,487
TrulicityDulaglutide87$114,397
JanuviaSitagliptin Phosphate175$109,381
LinzessLinaclotide113$75,335
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$54,709
VelphoroSucroferric Oxyhydroxide36$54,417
TradjentaLinagliptin110$44,331
XifaxanRifaximin26$39,433
AustedoDeutetrabenazine15$36,135
MounjaroTirzepatide29$36,059
EntrestoSacubitril/Valsartan56$33,560
XareltoRivaroxaban65$33,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$704$269,834412 claims
Novo NordiskOzempic$1,557$209,177175 claims
AstraZenecaFarxiga, Lokelma, Symbicort, Breztri Aerosphere$1,619$200,950305 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$829$164,298271 claims
PfizerEliquis$506$146,487336 claims
MerckJanuvia, Janumet, Janumet Xr$45$145,659205 claims
AbbVieLinzess$1,237$75,335113 claims
GSKTrelegy Ellipta, Breo Ellipta$311$52,11697 claims
Johnson & JohnsonXarelto, Invokana$232$47,18691 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$343$39,43326 claims
Teva Pharmaceuticals USA, Inc.Austedo$190$36,13515 claims
NovartisEntresto$541$33,56056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →